山东医科大学学报
山東醫科大學學報
산동의과대학학보
ACTA ACADEMIAE MEDICINAE SHANDONG
2001年
2期
152-154
,共3页
李晓梅%张友忠%刘序会%江森
李曉梅%張友忠%劉序會%江森
리효매%장우충%류서회%강삼
卵巢肿瘤%血管内皮生长因子%受体,血管内皮生长因子%免疫组织化学
卵巢腫瘤%血管內皮生長因子%受體,血管內皮生長因子%免疫組織化學
란소종류%혈관내피생장인자%수체,혈관내피생장인자%면역조직화학
研究血管内皮生长因子(VEGF)及其受体在卵巢癌组织中的表达及临床意义。方法:
应用免疫组化SABC法,检测33例上皮性卵巢癌、10例良性卵巢肿瘤、10例正常卵巢组织中VEGF及其受体VEGFR-1、VEGFR-2的表达,用Ⅷ因子单抗标记肿瘤新生血管内皮,计数微血管密度(MVD)。结果:VEGF及其受体VEGFR-1、VEGFR-2的表达在卵巢癌组织中显著高于良性及正常卵巢组织(P<0.05),且与卵巢癌患者临床分期、淋巴结转移、腹水癌细胞阳性、盆腔内形成粘连、MVD有明显相关性(P<0.05)。结论:VEGF及其受体是卵巢癌重要的血管生成调节系统,与卵巢癌发生、发展密切相关,以VEGF及其受体为靶点的抗血管生成疗法对卵巢癌是可行的。
研究血管內皮生長因子(VEGF)及其受體在卵巢癌組織中的錶達及臨床意義。方法:
應用免疫組化SABC法,檢測33例上皮性卵巢癌、10例良性卵巢腫瘤、10例正常卵巢組織中VEGF及其受體VEGFR-1、VEGFR-2的錶達,用Ⅷ因子單抗標記腫瘤新生血管內皮,計數微血管密度(MVD)。結果:VEGF及其受體VEGFR-1、VEGFR-2的錶達在卵巢癌組織中顯著高于良性及正常卵巢組織(P<0.05),且與卵巢癌患者臨床分期、淋巴結轉移、腹水癌細胞暘性、盆腔內形成粘連、MVD有明顯相關性(P<0.05)。結論:VEGF及其受體是卵巢癌重要的血管生成調節繫統,與卵巢癌髮生、髮展密切相關,以VEGF及其受體為靶點的抗血管生成療法對卵巢癌是可行的。
연구혈관내피생장인자(VEGF)급기수체재란소암조직중적표체급림상의의。방법:
응용면역조화SABC법,검측33례상피성란소암、10례량성란소종류、10례정상란소조직중VEGF급기수체VEGFR-1、VEGFR-2적표체,용Ⅷ인자단항표기종류신생혈관내피,계수미혈관밀도(MVD)。결과:VEGF급기수체VEGFR-1、VEGFR-2적표체재란소암조직중현저고우량성급정상란소조직(P<0.05),차여란소암환자림상분기、림파결전이、복수암세포양성、분강내형성점련、MVD유명현상관성(P<0.05)。결론:VEGF급기수체시란소암중요적혈관생성조절계통,여란소암발생、발전밀절상관,이VEGF급기수체위파점적항혈관생성요법대란소암시가행적。
To study the expression and clinical significae of vascular endothelial growth factor (VEGF) and its receptors in epithelial ovarian cancer. Methods: SABC immunohistochemical method was
used to investigate the expression of VEGF and its receptors in 33 samples of epithelial ovarian cancers(EOC),10 samples of benign tumors and 10 samples of normal ovarian tissue and MVD was counted with factor Ⅷ mono clone antigen as markers of newborn blood vessles. Results: The expression of VEGF and its receptors in EOC
was significantly higher than that in benign and normal ovarian tissues(P<0.05). The expression rates were as
sociated with clinical stage and lymphnode metastasis and ascites tumor cell and pelvic adhesion and MVD(P<
0.05). Conclusion:VEGF and its receptors are the important angiogenetic regulating system in EOC, correlated
with the occurrence and development of EOC. It's feasible to treate EOC with antiangiogenesis therapy targeting VEGF and its receptors.